Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Inclusion Criteria: * 18 Years to 70 Years，female * Histological diagnosis of squamous cell carcinoma of cervix, FIGO stage IIB-IVA,with diameter 4-6 cm, without distant metastasis. * no chance of surgery confirmed by more than two deputy chief doctors of gynecology. * Moderate or high expression of EGFR * The function of main organ is normal, including blood, heart, lung, liver, and kidney. Without history of hypertension, stroke. Blood pressure is normal before treatment. * WBC≥3.5×10E9/L，ANC≥1.5×10E9/L；HB≥90g/L，PLT≥100×10E9/L * ALT, AST and Cr below 1.5 times of normal level * Willing to accept treatment * Ability to comply with trial requirements KPS≥70 Exclusion Criteria: * Evidence of distance metastasis * Impossible to measure the diameter of tumor, or the tumor is too huge (diameter\>6cm) * Couldn't examine with pelvic MRI due to a variety of reasons * Used to treat with radiotherapy chemotherapy or molecular target therapy and immune therapy * Diagnosed with another malignant tumor in 5 years * Used to be a volunteer of other clinical trial. * Used to be allergic reaction with grade 3 or 4 degree to any experimental drugs * Severe medical history of lung ,liver, kidney or heart. * Active infection in any part of the whole body. * Examination results showed radiotherapy contraindications